Monitor for the filing of the resale registration statement and watch for any insider trading activity or follow-on commentary on clinical development timelines. The influx of cash extends the runway but adds meaningful dilution; assess whether upcoming catalysts justify the expanded share count.
RLMD drugs
RLMD drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 9 $7.17entry
- T+1 · 8mo ago −7.67%α −7.49% · $6.62
- T+5 · 8mo ago −13.81%α −12.45% · $6.18
- T+20 · 7mo ago −5.86%α −3.05% · $6.75
- T+60 · 6mo ago −10.46%α −22.45% · $6.42
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Relmada Therapeutics announced a $160 million PIPE financing through the sale of common stock and pre-funded warrants, with proceeds intended for R&D and general corporate purposes. The offering includes significant participation from major healthcare investors and is expected to close March 11, 2026, subject to customary conditions.
Key Financial Metrics
Key Facts
- Relmada raised $160 million in gross proceeds via a PIPE financing.
- The offering includes 29,474,569 shares of common stock at $4.75 per share and pre-funded warrants for 4,210,527 shares at $4.749 per warrant.
- Pre-funded warrants have an exercise price of $0.001 per share.
- Proceeds will fund working capital, R&D advancement, and general corporate purposes.
- Major institutional investors participated, including RA Capital, OrbiMed, Janus Henderson, and Balyasny.
- A registration rights agreement requires Relmada to file a resale registration statement with the SEC.
- Closing expected on or about March 11, 2026, subject to customary conditions.
Financial Impact
$160 million gross proceeds; significant near-term dilution from 33.7 million new shares (approx 14.3% of current shares outstanding assuming 235M prior float)
Risk Factors
- Significant shareholder dilution from issuance of ~33.7 million new shares and pre-funded warrants.
- Resale registration could increase near-term selling pressure as investors may flip shares.
- No guarantee that R&D spending will lead to clinical success or regulatory approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251705 |
Track record
11 reports on RLMD
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +38.81% at T+60 after the May 13, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $3.54 Now $3.61 −1.98% settles Dec 15
- Nov 16, 2026today 8-K Neutral 3/10 Entry $4.16 Now $3.61 −13.23% settles Dec 15
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $4.21 Now $3.61 −14.25% settles Dec 14
- Sep 11, 20269w ago Insider Cluster Bullish 6/10 Entry $4.52 to $3.39 Now $3.61 −20.13% ▼ −25.00% −26.87% vs SPY
- May 13, 202626w ago S-3ASR Bearish 6/10 Entry $7.42 to $6.65 Now $3.61 +51.35% ▲ +10.38% +9.52% vs SPY
- May 12, 202626w ago 8-K Neutral 4/10 Entry $7.49 to $6.52 Now $3.61 −51.80% ▼ −12.95% −12.34% vs SPY
- Apr 17, 202630w ago DEFA14A Neutral 3/10 Entry $7.37 to $6.34 Now $3.61 −51.02% ▼ −13.98% −18.18% vs SPY
- Apr 3, 202632w ago S-3 Neutral 3/10 Entry $6.90 to $7.41 Now $3.61 −47.68% ▲ +7.39% −1.59% vs SPY
- Mar 19, 202634w ago Press Release Bullish 8/10 Entry $6.07 to $7.37 Now $3.61 −40.53% ▲ +21.42% +12.10% vs SPY
- Mar 12, 202635w ago Press Release Neutral 3/10 Entry $6.15 to $7.29 Now $3.61 −41.30% ▲ +18.54% +16.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers